Avapritinib for advanced systemic mastocytosis: analysis of patient-reported outcomes from EXPLORER
1 Views
administrator
07/09/23
Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, discusses the analysis of the patient-reported outcomes data for avapritinib, a potent inhibitor of KIT D816V for advanced systemic mastocytosis. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
-
Category
Show more
Facebook Comments
No comments found